Michael Skynner, PH.D.

Michael Skynner, Ph.D., is chief operating officer at Bicycle Therapeutics responsible for global operations, the platform, discovery and strategic alliances. He has over 22 years of pharm/biotech experience and joined Bicycle in 2016 from Pfizer, where he led rare disease efforts in Europe and founded both the Pfizer Rare Disease Consortium & Genetic Medicine Institute. Previously, he established a discovery performance unit at GSK focused on developing clinical small-molecule therapeutics targeting inflammatory kinases. Prior to GSK he co-founded a successful peptide-based biotech start-up company, Cambridge Biotechnology Ltd., which was sold to Swedish Orphan Biovitrum.